Magenta Therapeutics

company

About

Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.

  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$50M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2015
Number Of Employee
51 - 100
Operating Status
Active

Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$102M
Magenta Therapeutics has raised a total of $102M in funding over 2 rounds. Their latest funding was raised on Apr 9, 2018 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 9, 2018 Series C $52M 1 Detail
May 2, 2017 Series B $50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Magenta Therapeutics is funded by 1 investors. Be The Match BioTherapies are the most recent investors.
Investor Name Lead Investor Funding Round
Be The Match BioTherapies Series C